Alkermes Plc (NASDAQ:ALKS) had its Buy rating reiterated by JPMorgan Chase & Co.

ME Staff
-
0

Analyst Ratings For Alkermes Plc (NASDAQ:ALKS)

Today, JPMorgan Chase & Co. reiterated its Buy rating on Alkermes Plc (NASDAQ:ALKS).

There are 5 Hold Ratings, 5 Buy Ratings, 3 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Alkermes Plc (NASDAQ:ALKS) is Hold with a consensus target price of $43.1818 per share, a potential 18.76% upside.

Some recent analyst ratings include

  • 4/10/2019-Alkermes Plc (NASDAQ:ALKS) had its Buy rating reiterated by JPMorgan Chase & Co.
  • 12/18/2018-Alkermes Plc (NASDAQ:ALKS) gets downgraded to Sell by Goldman Sachs Group with a price target of $26.00
  • 12/14/2018-Alkermes Plc (NASDAQ:ALKS) has coverage initiated with a Underperform ➝ Underperform rating
  • 11/12/2018-Alkermes Plc (NASDAQ:ALKS) has coverage initiated with a Market Perform rating and $36.00 price target
  • On 4/1/2019 Paul J Mitchell, Director, sold 1,000 with an average share price of $36.64 per share and the total transaction amounting to $36,640.00.
  • On 3/14/2019 Michael J Landine, SVP, sold 25,000 with an average share price of $33.05 per share and the total transaction amounting to $826,250.00.
  • On 3/13/2019 Richard F Pops, Director, sold 60,000 with an average share price of $33.32 per share and the total transaction amounting to $1,999,200.00.
  • On 3/7/2019 Michael J Landine, SVP, sold 20,000 with an average share price of $32.07 per share and the total transaction amounting to $641,400.00.
  • On 3/5/2019 Richard F Pops, Director, sold 50,000 with an average share price of $33.63 per share and the total transaction amounting to $1,681,500.00.
  • On 3/1/2019 Paul J Mitchell, Director, sold 1,000 with an average share price of $33.48 per share and the total transaction amounting to $33,480.00.
  • On 2/21/2019 Nancy Wysenski, Director, bought 3,857 with an average share price of $33.09 per share and the total transaction amounting to $127,628.13.

About Alkermes Plc (NASDAQ:ALKS)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Recent Trading Activity for Alkermes Plc (NASDAQ:ALKS)
Shares of Alkermes Plc closed the previous trading session at 36,36 +0,33 0,92 % with 36.14 shares trading hands.